中国首个获批结直肠癌的抗HER2产品！恒瑞ADC创新药艾维达®第3项适应症落地
Regulatoryapproved艾维达 (Aivida)Positive
AI Analysis
Summary
Hengrui Pharmaceuticals received Chinese regulatory approval for Aivida (recombinant humanized anti-HER2 monoclonal antibody-drug conjugate) as the first anti-HER2 product indicated for HER2-positive colorectal cancer, marking the drug's third approved indication following positive Phase 3 HORIZON-CRC01 trial results.
Clinical Trial Data
Outcome Details
China FDA approval for third indication; first anti-HER2 product approved in China for colorectal cancer; HORIZON-CRC01 Phase 3 trial showed positive results
Importance:8/10
Sentiment:
0.85
HER2ADCcolorectal cancerChina approvallabel expansioninnovative drug
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 7, 2026 1:07 AM